Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia

Maria Ilaria Del Principe, Michele Dal Bo, Tamara Bittolo, Francesco Buccisano, Francesca Maria Rossi, Antonella Zucchetto, Davide Rossi, Riccardo Bomben, Luca Maurillo, Mariagiovanna Cefalo, Giovanna De Santis, Adriano Venditti, Gianluca Gaidano, Sergio Amadori, Paolo de Fabritiis, Valter Gattei, Giovanni Del Poeta

Research output: Contribution to journalArticlepeer-review


In chronic lymphocytic leukemia the balance between the pro-apoptotic and anti-apoptotic members of the bcl-2 family is involved in the pathogenesis, chemorefractoriness and clinical outcome. Moreover, the recently proposed anti-bcl-2 molecules, such as ABT-199, have emphasized the potential role of of bcl-2 family proteins in the context of target therapies. We investigated bax/bcl-2 ratio by flow cytometry in 502 patients and identified a cut off of 1.50 to correlate bax/bcl-2 ratio with well-established clinical and biological prognosticators. Bax/bcl-2 was 1.50 or over in 263 patients (52%) with chronic lymphocytic leukemia. Higher bax/bcl-2 was associated with low Rai stage, lymphocyte doubling time over 12 months, beta-2 microglobulin less than 2.2 mg/dL, soluble CD23 less than 70 U/mL and a low risk cytogenetic profile (P

Original languageEnglish
Pages (from-to)77-85
Number of pages9
Issue number1
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this